← Therapy pipeline
Investigational · Obesity development

CagriSema

cagrilintide + semaglutide · Novo Nordisk

Two molecules in one injection: amylin analogue plus semaglutide.

GLP-1amylin
Other study areas
Type 2 diabetesCardiovascular outcomesWeight maintenance / switchingBody compositionPediatric weight management
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stageFiled for reviewUpdated as of November 2026
SponsorNovo Nordisk
TargetsGLP-1 + amylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

REDEFINE 1Mean body-weight changeBody weight decreased 20.4% · 68 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 68 weeks

Study focus: Weight management without type 2 diabetes

68-week Phase 3 trial in adults without type 2 diabetes; treatment-policy analysis.

Investigational regimen
20.4%
Placebo / comparator
3%

Adults with obesity, or overweight and an obesity-related complication · Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly vs placebo · Trial N=3417 · Treatment-policy estimand. Results & methods ↗

Additional results or analyses from this same study
  • REDEFINE 1 · post hoc early-response analysisAmong participants with less than 5% loss at week 8 and observed on-treatment week-68 data, mean weight loss was 17.8% and 37.2% achieved at least 20% loss. This selected, observed-data analysis is hypothesis-generating and does not validate a stopping rule. Follow-up source ↗

Gastrointestinal adverse events: 79.6% with combination versus 39.9% with placebo. The adherence-based estimate is a separate analysis.

REDEFINE 9Mean body-weight reductionBody weight decreased 21% · 68 weeks · Phase 3b
Phase 3b · Injection · Published trial; numbers from sponsor report

Mean body-weight reduction · 68 weeks

Study focus: Lower-dose weight management

Lower-dose CagriSema versus placebo in a 68-week randomized, double-blind trial.

CagriSema 1.0/1.0 mg
21%
Placebo
2%

Adults with obesity, or overweight with an obesity-related complication, without diabetes · Cagrilintide/semaglutide 1.0/1.0 or 1.7/1.7 mg weekly versus placebo · Trial N=309 · Efficacy estimand, assuming adherence; published trial reported by sponsor. Results & methods ↗ · Publication ↗

REDEFINE 9 · 68-week mean weight reduction by estimand
Weekly regimenEfficacy estimandTreatment-regimen estimand
1.7/1.7 mg20.7%19.4%
1.0/1.0 mg21.0%18.6%
Placebo2.0%4.6%
Additional results or analyses from this same study
  • Treatment-regimen estimandIncludes the effect of treatment discontinuation and use of weight-management rescue interventions. It is separate from the adherence-based efficacy estimand.

The two doses were tested against placebo; similar averages do not establish dose equivalence. Gastrointestinal events were most frequent and mainly mild to moderate. Adverse-event discontinuation was 2.9%, 4.9% and 4.9% with 1.7/1.7 mg, 1.0/1.0 mg and placebo, respectively.

REDEFINE 2Mean body-weight changeBody weight decreased 13.7% · 68 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 68 weeks

Study focus: Weight management with type 2 diabetes

68-week Phase 3 weight-management trial in adults with type 2 diabetes.

Investigational regimen
13.7%
Placebo / comparator
3.4%

Adults with BMI ≥27 and type 2 diabetes, baseline HbA1c 7–10% · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=1206 · Treatment-policy estimand. Results & methods ↗

REDEFINE 4Mean body-weight changeBody weight decreased 20.2% · 84 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight change · 84 weeks

Study focus: Comparative weight management

Head-to-head: weight-loss noninferiority was not demonstrated.

Investigational regimen
20.2%
Tirzepatide 15 mg
23.6%

Adults with obesity and at least one complication · CagriSema 2.4/2.4 mg vs tirzepatide 15 mg weekly · Trial N=809 · Treatment-regimen estimand; sponsor topline. Results & methods ↗

Open-label design. Efficacy-estimand reductions were 23.0% and 25.5%, respectively.

REDEFINE 5Mean body-weight changeBody weight decreased 18.4% · 68 weeks · Phase 3
Phase 3 · Injection · Peer-reviewed results

Mean body-weight change · 68 weeks

Study focus: Comparative weight management · Japan/Taiwan

Combination produced greater weight reduction than semaglutide alone.

Investigational regimen
18.4%
Semaglutide 2.4 mg
11.9%

Adults in Japan and Taiwan meeting regional BMI/complication criteria; 24% had type 2 diabetes · CagriSema 2.4/2.4 mg vs semaglutide 2.4 mg weekly · Trial N=331 · Published primary estimated mean change. Results & methods ↗

Diabetes-focused studies

These studies evaluate people with type 2 diabetes; their results are separate from trials without diabetes.

REIMAGINE 1Mean body-weight changeBody weight decreased 13.6% · 40 weeks · Phase 3
Phase 3 · Injection · Published trial; numbers from sponsor report

Mean body-weight change · 40 weeks

Study focus: Weight change in type 2 diabetes

HbA1c decreased 1.8 vs 0.4 percentage points.

Investigational regimen
13.6%
Placebo / comparator
1.4%

Type 2 diabetes inadequately controlled with diet and exercise · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=189 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗

REIMAGINE 2Mean body-weight changeBody weight decreased 12.9% · 68 weeks · Phase 3
Phase 3 · Injection · Published trial; numbers from sponsor report

Mean body-weight change · 68 weeks

Study focus: Weight change in type 2 diabetes

HbA1c decreased 1.80 vs 1.68 percentage points against semaglutide 2.4 mg.

Investigational regimen
12.9%
Semaglutide 2.4 mg
9.2%

Type 2 diabetes on metformin with or without an SGLT2 inhibitor · CagriSema 2.4/2.4 mg weekly vs semaglutide 2.4 mg · Trial N=2713 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗

REIMAGINE 3Mean body-weight changeBody weight decreased 11.3% · 40 weeks · Phase 3
Phase 3 · Injection · Published trial; numbers from sponsor report

Mean body-weight change · 40 weeks

Study focus: Weight change in type 2 diabetes

HbA1c decreased 2.26 vs 0.80 percentage points. Placebo weight increased.

Investigational regimen
11.3%
Placebo / comparator
0.8% increase

Type 2 diabetes treated with basal insulin, with or without metformin · CagriSema 2.4/2.4 mg weekly vs placebo · Trial N=274 · Treatment-regimen estimand; published trial reported by sponsor. Results & methods ↗ · Publication ↗

REIMAGINE 4Mean body-weight changeBody weight decreased 15.2% · 68 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight change · 68 weeks

Study focus: Weight change in type 2 diabetes

Weight noninferiority met; HbA1c noninferiority not met. Open-label trial.

Investigational regimen
15.2%
Tirzepatide 15 mg
15.8%

Type 2 diabetes on metformin with or without an SGLT2 inhibitor · CagriSema 2.4/2.4 mg vs tirzepatide 15 mg weekly · N not included in this summary · Efficacy estimand; sponsor report. Results & methods ↗

REIMAGINE 5Mean body-weight changeBody weight decreased 12.4% · 60 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight change · 60 weeks

Study focus: Weight change in type 2 diabetes

Weight superiority and HbA1c noninferiority met at these specific doses.

Investigational regimen
12.4%
Tirzepatide 5 mg
9.1%

Type 2 diabetes on metformin, an SGLT2 inhibitor or both · CagriSema 1.0/1.0 mg vs tirzepatide 5 mg weekly · N not included in this summary · Efficacy estimand; sponsor topline. Results & methods ↗

CagriSema Phase 2 · type 2 diabetesMean body-weight changeBody weight decreased 15.6% · 32 weeks · Phase 2
Phase 2 · Injection · Published trial; numbers from sponsor report

Mean body-weight change · 32 weeks

Study focus: Glycemic control and weight in type 2 diabetes

CagriSema
15.6%
Semaglutide
5.1%

Adults with type 2 diabetes and BMI ≥27 kg/m² on metformin with or without an SGLT2 inhibitor · Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly vs semaglutide 2.4 mg weekly · Trial N=92 · Published estimated mean changes; active-controlled randomized trial. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Third arm and primary endpoint · same studyCagrilintide alone reduced weight by 8.1%. HbA1c changes were −2.2, −1.8 and −0.9 percentage points with CagriSema, semaglutide and cagrilintide, respectively.

Small active-controlled trial with three arms and no placebo arm. HbA1c was the primary endpoint; the HbA1c difference versus semaglutide was not statistically significant.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Fixed-dose injectionInjection · Once weekly
FiledApplication submitted
Milestone → next

Latest: The U.S. weight-management application remains under review. Novo’s Q2 2026 pipeline update lists REDEFINE 11 and a separate higher-dose obesity program.

Next: REDEFINE 11 readout, expected in the first half of 2027, and further regulatory updates.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies14 records

Phase 3

Cagrilintide / CagriSema · pediatric study

Pediatric weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Shared protocol evaluating cagrilintide and CagriSema in children/adolescents; one protocol linked from both relevant profiles. Investigational pediatric use.

Phase 3b

CagriSema high-dose obesity program

Weight management
Study: PlannedResults: No results reported; study plannedStatus reviewed September 2026

Separate higher-dose development program; Novo’s Q2 2026 materials list it alongside Phase 3 obesity studies. No outcome data reported.

Phase 3

REDEFINE 11

Weight management and maintenance
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

80-week placebo-controlled study in adults with obesity; includes an extension studying maintenance of weight loss. Novo expects results in the first half of 2027.

Phase 3

REDEFINE 5

Weight management with type 2 diabetes
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

Adults in Japan and Taiwan meeting regional BMI/complication criteria; 24% had type 2 diabetes; 68 weeks.

Phase 3

REDEFINE 8

Body composition and weight maintenance
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

104-week study in adults with obesity, including body-composition assessment and an extension focused on weight-loss maintenance or dose tapering.

Phase 3b

REDEFINE 9

Weight management
Study: CompletedResults: Peer-reviewed results shown aboveStatus reviewed November 2026

309 adults without diabetes randomized to CagriSema 1.7/1.7 mg, 1.0/1.0 mg or placebo for 68 weeks. Efficacy and treatment-regimen estimands are reported separately.

Phase 3

REIMAGINE 4

Glycemic control and weight outcomes in type 2 diabetes
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

Type 2 diabetes on metformin with or without an SGLT2 inhibitor; 68 weeks.

Phase 2 studies1 record

Phase 2

CagriSema Phase 2 type 2 diabetes trial

Glycemic control and weight in type 2 diabetes
Study: CompletedResults: Published paper; sponsor figures shown aboveStatus reviewed November 2026

Published 32-week active-controlled study with 92 participants; primary HbA1c and secondary body-weight endpoints.

Related conditions and outcomes

Phase 3 studies1 record

Phase 3

REDEFINE 3

Cardiovascular outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Event-driven cardiovascular outcomes in adults with established cardiovascular disease, with or without type 2 diabetes.